Radhika Kainthla, M.D. is an Assistant Professor in the Department of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Hematology and Oncology. She specializes in malignant hematology and gastrointestinal oncology, practicing at Clements University Hospital and Parkland Memorial Hospital. At Parkland, she is the Medical Director of the Medical Oncology Clinics and the Cancer Liaison Physician for the Commission on Cancer.
A native of Texas, Dr. Kainthla received her undergraduate degree with honors in biochemistry from Southwestern University and her medical degree from UT Southwestern. She completed internal medicine residency training at Baylor College of Medicine. She then completed advanced training through a fellowship in hematology/oncology at UT Southwestern, where she served as Chief Fellow.
Certified by the American Board of Internal Medicine in hematology and medical oncology, Dr. Kainthla joined the UT Southwestern faculty in 2018.
Dr. Kainthla’s research interests include gastrointestinal oncology, malignant hematology, and quality improvement. Her investigations have resulted in several publications in peer-reviewed journals, as well as book chapters.
At UT Southwestern, Dr. Kainthla is Co-Director of the Frontiers in Neoplasia program and teaches medical and graduate students and fellows through lectures and clinic rotations. She received the “MVP for Microanatomy” teaching award in 2021.
Dr. Kainthla is a member of the Texas Medical Association, the American Medical Association, the Dallas County Medical Society, the American Society of Hematology, the American Society of Clinical Oncology, and the Texas Society of Clinical Oncology.
She was named a Rising Star in Texas Monthly’s Texas Super Doctors in 2020 and 2021.
Outside of medicine, Dr. Kainthla enjoys watching movies, spending time with her family, and playing/watching sports.
- Medical School
- UT Southwestern Medical School (2012)
- Baylor College of Medicine (2015), Internal Medicine
- UT Southwestern Medical Center (2018), Hematology Oncology
- Gastrointestinal Oncology
- Malignant Hematology
- Quality Improvement
- Adjuvant chemotherapy for ypT0N0M0 rectal cancer following chemoradiotherapy and total mesorectal excision.
- Kainthla R, Huerta S Anticancer Drugs 2016 Jul
- Dabrafenib for treatment of BRAF-mutant melanoma.
- Kainthla R, Kim KB, Falchook GS Pharmgenomics Pers Med 2014 7 21-9
- Regulation of telomerase alternative splicing: a target for chemotherapy.
- Wong MS, Chen L, Foster C, Kainthla R, Shay JW, Wright WE Cell Rep 2013 Apr 3 4 1028-35
Leukemia. In Handbook of Targeted Cancer Therapy
Kainthla R, Kadia TM, Pennaraju N (2015). Phildelphia, PA, Wolters Kluwer
Small Molecules in Oncology: Dabrafenib. In Recent Results in Cancer Research
Kainthla R, Kim, KB, Falchook GS (2014). Heidelberg, Springer
Honors & Awards
- Hematology/Oncology Chief Fellow Award
UT Southwestern (2017-2018)
- American Medical Association (2012)
- American Society of Clinical Oncology (2015)
- American Society of Hematology (2015)
- Dallas County Medical Society (2015)
- Texas Medical Association (2008)